Genetic study paves way for new neuropathic pain treatments

A pioneering, multi-institutional research group has conducted an in-depth analysis of the molecular differences between the most common symptoms associated with neuropathic pain. The project may pave the way for the development of more effective painkillers for the treatment of this debilitating chronic condition, which afflicts approximately 500 million people throughout the world.

An injury afflicting in the nervous system can give rise to a very specific condition known as neuropathic pain. The research study, conducted on mice, has examined the profile of the genetic changes that occur following these nerve injuries and aims to broaden the understanding of the mechanisms responsible for neuropathic pain.

When an individual suffers from this , sensory stimuli such as temperature (especially cold sensations) and tactile sensations, which under normal circumstances do not generally cause pain, are interpreted by the nervous system as acutely painful. This abnormal response to stimuli is called allodynia.

Not all patients experience these painful symptoms with the same level of intensity, and some react more adversely than others to cold temperatures (cold allodynia) as opposed to (tactile allodynia), and vice versa.

This pioneering new study demonstrates that the causes of cold allodynia are exclusively neuronal in nature, and that it is a direct response to the nerve injury, while tactile allodynia is the result of complex interactions between the immune system and the nervous system. Consequently, the diverse manifestations of neuropathic pain have different cellular origins and therefore patients suffering from cold or tactile allodynia may be in need of different therapeutic strategies to treat their specific .

According to Dr. Enrique J. Cobos del Moral, one of the main researchers behind the project, "taking an in-depth look at the molecular differences between the most common symptoms associated with could lead to the development of more effective painkillers to alleviate this type of , designed to treat the specific symptoms experienced by each patient."

More information: Enrique J. Cobos et al, Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling, Cell Reports (2018). DOI: 10.1016/j.celrep.2018.01.006

Journal information: Cell Reports
Citation: Genetic study paves way for new neuropathic pain treatments (2018, February 22) retrieved 28 March 2024 from https://medicalxpress.com/news/2018-02-genetic-paves-neuropathic-pain-treatments.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers identify root of chronic pain as potential new drug target

5 shares

Feedback to editors